Search
Urethane
go.drugbank.com/drugs/DB04827ApprovedWithdrawnUrethane, formerly marketed as an inactive ingredient in Profenil injection, was determined to be carcinogenic and was removed from the Canadian, US, and UK markets in 1963.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2E1 SubstratesFluspirilene
go.drugbank.com/drugs/DB04842ApprovedWithdrawnA long-acting injectable antipsychotic agent used for chronic schizophrenia.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesFebuxostat
go.drugbank.com/drugs/DB04854ApprovedInvestigationalFebuxostat is a non-purine xanthine oxidase (XO) inhibitor. In early 2008, febuxostat was granted marketing authorization by the European Commission for the treatment of chronic hyperuricemia and gout. In the following year, the FDA for ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesDronedarone
go.drugbank.com/drugs/DB04855ApprovedInvestigationalDronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primaril...
Synonyms: N-(2-butyl-3-(p-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamideCategories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesDexloxiglumide
go.drugbank.com/drugs/DB04856InvestigationalDexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist in phase III testing by Rottapharm in Europe only, as U.S. trials have been discontinued. As the D-isomer of loxiglumide, it retains all pharmacological prop...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesLorcaserin
go.drugbank.com/drugs/DB04871ApprovedInvestigationalWithdrawnLorcaserin (previously APD-356), a highly selective 5HT2C receptor agonist, is used for the treatment of obesity. It has been shown to reduce body weight and food intake in animal models of obesity, and it is thought that targeting the 5...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesVoacamine
go.drugbank.com/drugs/DB04877ExperimentalVoacamine is an alkaloid isolated from the bark of the Pescheria fuchsiae folia tree. It is an antimalarial drug approved for use in several African countries. Voacamine is also under investigation for use in modulating multidrug-resista...
Categories: P-glycoprotein inhibitorsTopiroxostat
go.drugbank.com/drugs/DB01685InvestigationalTopiroxostat is a selective xanthine oxidase inhibitor developed for treatment and management of hyperuricemia and gout. Xanthine oxidase, or xanthine oxidoreductase (XOR), regulates purine metabolism, and inhibition of the enzyme result...
Categories: Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C8 InhibitorsPrasterone
go.drugbank.com/drugs/DB01708ApprovedInvestigationalNutraceuticalPrasterone, also known as dehydroepiandrosterone (DHEA) is a major C19 steroid produced by the adrenal cortex. It is also produced in small quantities in the testis and the ovary. Dehydroepiandrosterone (DHEA) can be converted to testost...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsStaurosporine
go.drugbank.com/drugs/DB02010ExperimentalAn indolocarbazole that is a potent protein kinase C inhibitor which enhances cAMP-mediated responses in human neuroblastoma cells. (Biochem Biophys Res Commun 1995;214(3):1114-20)
Categories: P-glycoprotein inhibitors